Evidence Snapshot

GABA A receptor alpha-1/beta-1/gamma-2

CHEMBL2111392 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:13Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2111392

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats GABA A receptor alpha-1/beta-1/gamma-2 as ChEMBL target CHEMBL2111392, mapped to UniProt P14867. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

GABA A receptor alpha-1/beta-1/gamma-2

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2111392

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P14867

Gamma-aminobutyric acid receptor subunit alpha-1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why GABA A receptor alpha-1/beta-1/gamma-2 matters

As of 2026-09-13

GABA A receptor alpha-1/beta-1/gamma-2 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-1 (UniProt P14867); GABA A receptor alpha-1/beta-1/gamma-2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 38 compounds, and 25 assays, with lead potency reaching pChEMBL 9.6.

Protein context

Gamma-aminobutyric acid receptor subunit alpha-1

Gamma-aminobutyric acid receptor subunit alpha-1 Sequence length is 456 aa.

Review this target as GABA A receptor alpha-1/beta-1/gamma-2, mapped to UniProt P14867. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit alpha-1. Sequence length is 456 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P14867 Protein

Disease context

insomnia

GABA A receptor alpha-1/beta-1/gamma-2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ZALEPLON, ZOLPIDEM TARTRATE.

Start review with insomnia because it currently carries approved-linked support. Linked drugs include ZALEPLON, ZOLPIDEM TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 2 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 38 compounds, and 25 assays for this target. The dominant activity type is EC50. CHEMBL381059 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL381059 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine

4 approved pChEMBL 9.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why GABA A receptor alpha-1/beta-1/gamma-2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14867, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why insomnia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 4.0, KI: 6.0, EC50: 24.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL381059	9.6	Ki	—
No preferred name CHEMBL206071	8.4	Ki	—
No preferred name CHEMBL12	7.9	Ki	Approved
No preferred name CHEMBL205257	7.8	Ki	—
No preferred name CHEMBL229534	7.5	EC50	—